Review
Oncology
Tian Tian, Zhaoming Li
Summary: Blocking therapy targeting programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) has revolutionized the treatment of malignant tumors, but patient response rates are low and drug resistance is a major concern. Combining this therapy with Tim-3 blockade may offer a promising approach to overcoming resistance in cancer immunotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Endocrinology & Metabolism
Xiao Shi, Cui-Wei Li, Li-Cheng Tan, Shi-Shuai Wen, Tian Liao, Yan Zhang, Tong-Zhen Chen, Ben Ma, Peng-Cheng Yu, Zhong-Wu Lu, Ning Qu, Yu Wang, Rong-Liang Shi, Yu-Long Wang, Qing-Hai Ji, Wen-Jun Wei
Summary: This study investigated the expression profiles of immune co-inhibitory receptors in medullary thyroid carcinoma patients, identifying TIM-3 and CTLA-4 expression as potentially promising biomarkers for tumor recurrence. The findings suggest that advanced MTCs may be immunogenic and could benefit from immune therapy targeting these receptors.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Oncology
Christina Bruss, Kerstin Kellner, Veruschka Albert, James A. Hutchinson, Stephan Seitz, Olaf Ortmann, Gero Brockhoff, Anja K. Wege
Summary: Immunotherapies can be used to treat various cancers, but many patients do not respond well and develop resistance, so specific treatment combinations are needed to improve efficacy. Combined anti-PD-1/anti-LAG-3 therapy has been approved for melanoma patients. Humanized tumor mouse models can be used as an important tool for preclinical immunotherapeutic trials.
Review
Biochemistry & Molecular Biology
Xianjing Chu, Wentao Tian, Ziqi Wang, Jing Zhang, Rongrong Zhou
Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by offering long-lasting responses and survival benefits. However, response rates vary among individuals and cancer types, leading to the proposal of dual ICI combination therapy. TIGIT, an inhibitory receptor associated with T-cell exhaustion, has diverse immunosuppressive effects and can synergize with PD-1/PD-L1 blockade to enhance tumor rejection. Preclinical studies have shown potential benefits, and clinical trials are underway to evaluate the safety and efficacy of TIGIT and PD-1/PD-L1 co-inhibition. Overall, co-inhibition of TIGIT and PD-1/PD-L1 represents a promising approach to improve outcomes for cancer patients treated with ICIs.
Review
Biochemistry & Molecular Biology
Negar Hosseinkhani, Mahdi Abdoli Shadbad, Mohammad Asghari Jafarabadi, Noora Karim Ahangar, Zahra Asadzadeh, Seyede Momeneh Mohammadi, Parisa Lotfinejad, Nazila Alizadeh, Oronzo Brunetti, Rossella Fasano, Nicola Silvestris, Behzad Baradaran
Summary: Our systematic review and meta-analysis found that increased TIGIT expression is significantly associated with inferior overall survival in patients with solid cancers. Additionally, the infiltration of TIGIT(+)CD8(+) T-cells is also linked to worse outcomes in affected patients. Furthermore, a strong positive association between TIGIT expression and programmed cell death-1 (PD-1) expression was observed in these patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Immunology
Julia A. Penatzer, Robin Alexander, Shan Simon, Amber Wolfe, Julie Breuer, Josey Hensley, Renata Fabia, Mark Hall, Rajan K. Thakkar
Summary: Thermal injury in pediatric population can lead to immune dysfunction and increased risk of infections. This study found that both innate and adaptive immune functions are suppressed within 72 hours after burn injury in children, and the presence of certain soluble protein markers is associated with the development of nosocomial infections.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Shuxin Huang, Yujie Zhao, Pengjun Liao, Jinghua Wang, Zhiyan Li, Jiaxiong Tan, Xianfeng Zha, Shaohua Chen, Yangqiu Li, Liye Zhong
Summary: This study aimed to investigate the expression and immunosuppressive role of VISTA in multiple myeloma (MM). The results showed a significant increase in the co-expression of VISTA with PD-1, Tim-3, and TIGIT in T cells of MM patients, which was closely associated with disease progression and clinical indicators.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Tiziana Annese, Roberto Tamma, Domenico Ribatti
Summary: This article discusses the interaction between tumor cells and T cells, with a focus on the role of TIGIT in immune cells. It proposes therapeutic strategies for cancer treatment by targeting the TIGIT pathway.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Negar Hosseinkhani, Mahdi Abdoli Shadbad, Mohammad Asghari Jafarabadi, Noora Karim Ahangar, Zahra Asadzadeh, Seyede Momeneh Mohammadi, Parisa Lotfinejad, Nazila Alizadeh, Oronzo Brunetti, Rossella Fasano, Nicola Silvestris, Behzad Baradaran
Summary: High TIGIT expression and increased infiltration of TIGIT(+)CD8(+) T-cells are significantly associated with poor prognosis in patients with solid cancers, and there is a strong positive association between TIGIT expression and programmed cell death-1 (PD-1) expression. This suggests that a dual blockade of PD-1/TIGIT could potentially address immune resistance in solid cancer patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Menghan Wu, Aijun Wu, Xiangrui Zhang, Yang Li, Beibei Li, Shengzhe Jin, Qingyu Dong, Xiaoshuang Niu, Lihan Zhang, Xiaowen Zhou, Jiangfeng Du, Yahong Wu, Wenjie Zhai, Xiuman Zhou, Lu Qiu, Yanfeng Gao, Wenshan Zhao
Summary: PD-1/PD-L1 blockade has shown significant clinical outcomes in cancer treatment, but the presence of other immune checkpoints reduces its efficacy. Targeting TIM-3 with small molecule inhibitors is a promising strategy for cancer immunotherapy.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Cell Biology
Pauline Weimer, Jasmin Wellbrock, Tabea Sturmheit, Leticia Oliveira-Ferrer, Yi Ding, Stephan Menzel, Marius Witt, Louisa Hell, Barbara Schmalfeldt, Carsten Bokemeyer, Walter Fiedler, Franziska Brauneck
Summary: This study found a high prevalence of V δ1 T cells in the malignant ascites lymphocytes (MALs) and tumor infiltrating lymphocytes (TILs) of ovarian cancer patients. These cells exhibited different differentiation states, and V δ1 T cells in TILs showed the highest levels of expression for TIGIT, PD-1, and CD39, which provides hope for therapeutic strategies based on V δ1 T cells and these receptors.
Article
Immunology
Abdo Meyiah, Ghanbar Mahmoodi Chalbatani, Mohamed A. Al-Mterin, Mohammad Amin Malekraeisi, Khaled Murshed, Eyad Elkord
Summary: Immune checkpoints expressed on tumor-infiltrating CD8+ T cells are significantly associated with disease-free survival (DFS) in colorectal cancer patients. In particular, the co-expression of TIGIT+ and TIM-3+ tumor-infiltrating CD8+ T cells with PD-1+ is strongly correlated with longer DFS. This study highlights the importance of immune checkpoint expression on tumor-infiltrating CD8+ T cells as critical predictive biomarkers, especially when considering the co-expression of different immune checkpoints.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Multidisciplinary Sciences
Kimiharu Takamatsu, Nobuyuki Tanaka, Kyohei Hakozaki, Ryohei Takahashi, Yu Teranishi, Tetsushi Murakami, Ryohei Kufukihara, Naoya Niwa, Shuji Mikami, Toshiaki Shinojima, Takashi Sasaki, Yusuke Sato, Haruki Kume, Seishi Ogawa, Kazuhiro Kakimi, Takashi Kamatani, Fuyuki Miya, Tatsuhiko Tsunoda, Eriko Aimono, Hiroshi Nishihara, Kazuaki Sawada, Takeshi Imamura, Ryuichi Mizuno, Mototsugu Oya
Summary: Targeting inhibitory receptors (IRs) LAG-3, TIM-3, and TIGIT in immunotherapy for human renal cell carcinoma is promising, with individual IR levels serving as potential biomarkers for analysis. The immunogenomic landscape of the disease can be investigated through automated single-cell counting for these IRs.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
Yaping Chen, Hao Huang, Yuan Li, Wenlu Xiao, Yingting Liu, Rongzhang Chen, Yulan Zhu, Xiao Zheng, Changping Wu, Lujun Chen
Summary: Combination immunotherapy based on immune checkpoint inhibitors (ICIs) has shown great success in cancer treatment, and the combination of ablation and immunotherapy has potential for the treatment of liver metastasis of colorectal cancer (CRC). The expression of TIGIT was up-regulated after microwave ablation (MWA), and the combination of MWA and TIGIT blockade significantly promoted the expansion and functions of CD8(+) tumor-infiltrating lymphocytes (TILs) and reshaped myeloid cells in the tumor microenvironment (TME).
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Shengming Jin, Zhi Shang, Wenwen Wang, Chengyuan Gu, Yu Wei, Yu Zhu, Chen Yang, Tiantian Zhang, Yao Zhu, Yiping Zhu, Junlong Wu, Dingwei Ye
Summary: This study aimed to investigate the expression and clinical significance of immune co-inhibitory receptors in Chinese patients with upper tract urothelial carcinoma. CTLA-4 and TIGIT expression were found to be associated with tumor recurrence, and a subset of advanced UTUCs may have immunogenicity, suggesting the potential use of single or combined immunotherapy in the future.
JOURNAL OF IMMUNOTHERAPY
(2023)
Review
Biochemistry & Molecular Biology
Shreyas Gaikwad, Sanjay K. Srivastava
Summary: Research has shown that ROS play a critical role in cancer by activating oncogenic pathways or inducing cell death. Phytochemicals are considered potential strategies in cancer treatment due to their ability to influence ROS homeostasis and favorable side effect profile.
Article
Biochemistry & Molecular Biology
Nehal Gupta, Shreyas Gaikwad, Itishree Kaushik, Stephen E. Wright, Maciej M. Markiewski, Sanjay K. Srivastava
Summary: Atovaquone reduces the growth of triple-negative breast tumors by decreasing immunosuppressive cells, cytokines, and regulatory T cells in the tumor microenvironment, showing potential as an anticancer therapeutic strategy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Yige Fu, Aishwarya Saraswat, Zenghui Wei, Manas Yogendra Agrawal, Vikas V. Dukhande, Sandra E. Reznik, Ketan Patel
Summary: ARNIPL, a novel combination of ARV-825 and nintedanib loaded in PEGylated nanoliposomes, showed enhanced cytotoxicity, apoptosis, and down-regulation of target proteins in vemurafenib-resistant melanoma cells. It also significantly inhibited vasculogenic mimicry and clonogenic potential of A375R, and reduced tumor growth in 3D spheroids. ARNIPL could be a promising therapeutic approach for the treatment of vemurafenib-resistant melanoma.
Article
Oncology
Itishree Kaushik, Sharavan Ramachandran, Carson Zabel, Shreyas Gaikwad, Sanjay K. Srivastava
Summary: Immune checkpoint inhibitors have revolutionized cancer immunotherapy, but their efficacy is limited to specific tumor types and is often accompanied by resistance and immune-related adverse effects.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Oncology
Hong-My Nguyen, Shreyas Gaikwad, Mariam Oladejo, Manas Yogendra Agrawal, Sanjay K. Srivastava, Laurence M. Wood
Summary: Type 1 interferons are central in regulating the immune system's response and induce interferon-stimulated genes (ISGs). Among them, ISG15 has been extensively studied for its role in cancer as both a promoter and inhibitor of tumor growth. This review provides an update on recent observations and findings related to ISG15 in cancer, including its molecular mechanisms and therapeutic applications.
Article
Oncology
Hong-My Nguyen, Shreyas Gaikwad, Mariam Oladejo, Wyatt Paulishak, Laurence M. Wood
Summary: This study investigated the therapeutic efficacy of Listeria-based vaccines targeting ISG15 in colorectal cancer (CRC), and found that the vaccine can effectively recruit cytotoxic T lymphocytes and regulate the tumor microenvironment to achieve anti-tumor efficacy against the MC38 tumor model.
Review
Oncology
Manas Yogendra Agrawal, Shreyas Gaikwad, Sangeeta Srivastava, Sanjay K. Srivastava
Summary: Cancer is a leading cause of death worldwide. The study of bioactive components in food and their molecular mechanisms for anticancer effects has been increasing over the decades. Probiotics also play a role in cancer prevention and treatment through immunomodulatory effects. Combining bioactive agents with chemotherapy and novel delivery techniques enhance their therapeutic response.
Article
Respiratory System
Amit R. Agarwal, Smita Kadam, Ankita Brahme, Manas Agrawal, Komalkirti Apte, Govinda Narke, Kushal Kekan, Sapna Madas, Sundeep Salvi
RESPIRATORY RESEARCH
(2019)
Meeting Abstract
Respiratory System
Ankita Brahme, Smita Kadam, Manas Agrawal, Komalkirti Apte, Govinda Narke, Sapna Madas, Sundeep Salvi, Amit Agarwal
EUROPEAN RESPIRATORY JOURNAL
(2018)